SomaGenics was incorporated in 1997 as a technology spin-out from SRI International. It was first established in Palo Alto and moved to its current location in Santa Cruz in 1999.
From its inception, the company’s goal has been to develop innovative products based on high-quality science. SomaGenics has been awarded a total of $20 million in competitive grants through the National Institutes of Health, DARPA, NSF, and others. Where consistent with protection of the company's intellectual property, SomaGenics has a policy of publishing its findings in respected peer-reviewed scientific journals.
SomaGenics has enjoyed fruitful collaborations with a number of top academic institutions, including Stanford, Princeton, Texas A&M, University of Texas/MD Anderson Cancer Center, City of Hope National Medical Center, Georgetown University, Indiana University, Harvard Medical School, UC Los Angeles, UC San Francisco and UC Santa Cruz.
Somagenics has also collaborated with corporate partners, including Tekmira and Roche.
We welcome inquiries for further collaborations.